

MEETING REPORT

Open Access



Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group

Kamala Thriemer^{1*}, Albino Bobogare², Benedikt Ley¹, Clarice Samo Gudo³, Mohammad Shafiul Alam⁴, Nick M. Anstey¹, Elizabeth Ashley^{5,6}, J. Kevin Baird^{6,7}, Charlotte Gryseels⁸, Elodie Jambert⁹, Marcus Lacerda^{10,11}, Ferdinand Laihad¹², Jutta Marfurt¹, Ayodhia Pitaloka Pasaribu¹³, Jeanne Rini Poespoprodjo¹⁴, Inge Sutanto¹⁵, Walter R. Taylor^{6,16}, Christel van den Boogaard¹, Katherine E. Battle¹⁷, Lek Dysoley^{18,19}, Prakash Ghimire²⁰, Bill Hawley²¹, Jimmie Hwang^{22,23}, Wasif Ali Khan⁴, Rose Nani Binti Mudin²⁴, Maria Endang Sumiwi²⁵, Rukhsana Ahmed²⁶, M. M. Aktaruzzaman²⁷, Kiran Raj Awasthi²⁸, Azucena Bardaji²⁹, David Bell³⁰, Leonard Boaz², Faustina Helen Burdam¹⁴, Daniel Chandramohan³¹, Qin Cheng³², Keobouphaphone Chindawongsa³³, Janice Culpepper³⁴, Santasabuj Das³⁵, Raffy Deray³⁶, Meghna Desai³⁷, Gonzalo Domingo³⁸, Wang Duoquan³⁹, Stephan Duparc⁹, Rustini Floranita⁴⁰, Emily Gerth-Guyette³⁸, Rosalind E. Howes¹⁷, Cecilia Hugo⁴¹, George Jagoe⁹, Elvieda Sariwati⁴², Sanya Tahmina Jhora²⁷, Wu Jinwei⁴³, Harin Karunajeewa⁴⁴, Enny Kenangalem¹⁴, Bibek Kumar Lal⁴⁵, Chandra Landuwulang⁴⁶, Emmanuel Le Perru⁴⁷, Sang-Eun Lee⁴⁸, Leo Sora Makita⁴⁹, James McCarthy⁵⁰, Asrat Mekuria⁵¹, Neelima Mishra³⁵, Esau Naket⁵², Simone Nambanya³³, Johnny Nausien⁵², Thang Ngo Duc⁵³, Thuan Nguyen Thi⁵³, Rinitis Noviyanti⁵⁴, Daniel Pfeffer^{1,17}, Gao Qi^{55,56}, Annisa Rahmalia^{57,58}, Stephen Rogerson⁵⁹, Iriani Samad⁴², Jetsumon Sattabongkot⁶⁰, Ari Satyagraha⁵⁴, Dennis Shanks³², Surender Nath Sharma⁶¹, Carol Hopkins Sibley^{62,63}, Ali Sungkar⁶⁴, Din Syafruddin⁵⁴, Arunansu Talukdar⁶⁵, Joel Tarning¹⁶, Feiko ter Kuile^{26,66}, Suman Thapa²⁸, Minerva Theodora⁴², Tho Tran Huy⁵³, Edward Waramin⁶⁷, Govert Waramori⁶⁸, Adugna Woyessa⁶⁹, Chansuda Wongsrichanalai⁷⁰, Nguyen Xuan Xa⁵³, Joon Sup Yeom⁷¹, Lukas Hermawan⁶⁴, Angela Devine^{1,6,16}, Spike Nowak³⁸, Indra Jaya⁷², Supargiyono Supargiyono⁷³, Koen Peeters Grietens⁸ and Ric N. Price^{1,6}

Abstract

The goal to eliminate malaria from the Asia-Pacific by 2030 will require the safe and widespread delivery of effective radical cure of malaria. In October 2017, the Asia Pacific Malaria Elimination Network Vivax Working Group met to discuss the impediments to primaquine (PQ) radical cure, how these can be overcome and the methodological difficulties in assessing clinical effectiveness of radical cure. The salient discussions of this meeting which involved 110 representatives from 18 partner countries and 21 institutional partner organizations are reported. Context specific strategies to improve adherence are needed to increase understanding and awareness of PQ within affected communities; these must include education and health promotion programs. Lessons learned from other disease programs highlight that a package of approaches has the greatest potential to change patient and prescriber habits, however optimizing the components of this approach and quantifying their effectiveness is challenging. In a trial setting, the

*Correspondence: kamala.ley-thriemer@menzies.edu.au

¹ Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Darwin, NT 0810, Australia
Full list of author information is available at the end of the article



reactivity of participants results in patients altering their behaviour and creates inherent bias. Although bias can be reduced by integrating data collection into the routine health care and surveillance systems, this comes at a cost of decreasing the detection of clinical outcomes. Measuring adherence and the factors that relate to it, also requires an in-depth understanding of the context and the underlying sociocultural logic that supports it. Reaching the elimination goal will require innovative approaches to improve radical cure for vivax malaria, as well as the methods to evaluate its effectiveness.

Keywords: Vivax malaria, *Plasmodium vivax*, Adherence, Effectiveness, Efficacy, Radical cure, Primaquine, APMEN

Background

In November 2014 the governments of the Asia-Pacific nations reconfirmed their commitment to the regional malaria elimination by 2030 [1]. Over the last decade major gains in malaria control have been made, but these successes have been far less apparent for *Plasmodium vivax* than for *Plasmodium falciparum*. One of the greatest challenges in achieving the ambitious goal of malaria elimination is widespread implementation of the effective radical cure of malaria, in which all stages of the parasite are targeted. The propensity of *P. vivax* to form dormant liver stages (hypnozoites) and to recur, requires the provision of treatment of both the blood and liver stages of the parasite [2]. Currently, the only widely available drug to eliminate hypnozoites from the human host is primaquine (PQ). The World Health Organization (WHO) treatment guidelines recommend that PQ is administered over 14 days to reduce the risk of severe haemolysis [3]. Tafenoquine (TQ), another investigational 8-aminoquinoline compound currently under review by US Food and Drug Administration and the Australian Therapeutic Goods Administration, has a significantly longer half-life than PQ and, therefore, can be administered as a single dose regimen. However, the prolonged drug concentrations raise concerns over its potential to cause sustained haemolysis in G6PD intermediate and deficient individuals, highlighting the need for appropriate G6PD screening.

When supervised, a 14-day regimen of PQ can reduce the risk of recurrent *P. vivax* infection by more than 85% [4, 5]. However in most clinical scenarios daily supervision of a prolonged treatment regimen is not feasible. When drug administration is not supervised the clinical effectiveness of a 14-day course of PQ can be compromised severely [5–9]. In a recent large-scale observational study of 68,000 patients with vivax malaria in Papua, Indonesia, the effectiveness of unsupervised PQ was estimated to be at best 12% [10]. Whilst adherence to a 14 days regimen can be mitigated by reducing the duration of treatment [11], even an unsupervised 7 days regimen has been shown to be suboptimal [12]. Radical cure with a single dose of TQ will overcome many of the issues of adherence, however the challenges of ensuring

concomitant G6PD testing will ensure that in many locations PQ regimens will still be the only available treatment option. Thus there is an urgent need to understand the determinants of adherence and to develop innovative approaches to improve anti-malarial effectiveness in malaria endemic areas. Investigation, rationalization and validation of novel interventions to improve adherence, requires measuring clinical effectiveness and this also poses specific challenges above and beyond conventional efficacy clinical trials.

As part of the ongoing collaborative efforts towards the elimination of malaria in the Asia-Pacific region, the annual meeting of the Vivax Working Group (VxWG) of the Asia-Pacific Malaria Elimination Network (APMEN) [13] was convened in Bali, Indonesia, in October 2017. The meeting was attended by 110 representatives from 18 partner countries and 21 institutional partner organizations. Data were presented on the challenges of adherence to antimalarial treatment regimens, lessons from the management of other infectious diseases, and clinical trials methodology. In addition two round table discussions were held to discuss (i) whether adherence to PQ radical cure was an issue, and if so how this could be overcome and (ii) methodological challenges in assessing anti-malarial efficacy and effectiveness of *P. vivax* infection. The specific questions posed to the groups are listed in Tables 1 and 2. The key discussion points are summarized into 4 categories: (i) impediments to PQ adherence at the level of the patient and health system, and suitable strategies to overcome these, (ii) tools and strategies that can be used from other disease programmes to improve adherence, (iii) measuring the effectiveness of PQ radical cure, and (iv) increasing the understanding of effectiveness and adherence using mixed methods research.

Topic 1: Impediments to PQ adherence at the level of the patient and health system, and suitable strategies to overcome these

Vivax malaria is often perceived as a benign disease and there is a lack of understanding and awareness regarding the benefits of radical cure; this constitutes the main impediment for PQ adherence at the patient level. There

Table 1 Questions posed to participants for the first round table discussion

What are the main impediments of adherence from a patient perspective?
What are the main impediments of adherence from health care system perspective?
How can adherence be improved on the patient level?
How can adherence be improved on a health care system level?
Can methods from other disease programs be applied to malaria?
How can adherence to radical cure guidelines be improved?
How and what methods to increase adherence can be integration into current infrastructure?
What research is needed to better inform programs to improve adherence?

Table 2 Questions posed to participants for the second round table discussion

Quantifying effectiveness: what outcome measures are needed?
Quantifying effectiveness: how can observer bias be minimized?
How can adherence be assessed in study setting/real life?
What should be priorities in qualitative surveys around adherence?
What public health interventions are needed to increase effectiveness of PQ?

is a disconnect with the treatment of an acute febrile illness and the subsequent high risk of recurrent episodes of malaria, which are often regarded as new infections. Adherence to medication is influenced by a combination of social representation of medicines, such as the cultural and social meanings attributed to drugs and the cultural constructions of certain brand names [14, 15].

The beliefs among healthcare workers and policy makers were also regarded as being crucial, and these result in low rates of prescription, even when PQ is part of local and national treatment guidelines [16]. The perceived lack of benefit of radical cure is compounded in some locations by concerns regarding the potential side-effects of PQ, particularly the risk of haemolysis. Concerns regarding haemolysis and PQ toxicity, were apparent particularly in areas where G6PD deficiency could not be diagnosed reliably [16]. The lack of clear protocols to monitor and report haemolytic events after PQ treatment were mentioned as additional concerns. The acute febrile illness of vivax malaria is treated with standard schizontocidal drugs, but the additional prescription of PQ for the prevention of future recurrent infections is often regarded as being of secondary importance. Hence, concerns regarding potential adverse effects and the lack of immediate benefits, influence prescribing habits.

The need for better staff training and increased awareness about the individual and community benefits of radical cure were identified as a key strategy to overcome poor adherence by both the patient and the health provider. Participants highlighted the need for context specific strategies to improve adherence, including education and health promotion programmes aimed at increasing

understanding and awareness within affected communities. Other interventions perceived as potentially beneficial included more intensive patient monitoring, which could be integrated with other disease programmes or home visits. This would reassure clinicians that if adverse events occurred they would be identified and managed promptly. Incentives could be devised to encourage providers to prescribe PQ and intermittent reminders could be provided to patients through mobile phone technologies to prompt them to continue treatment after their symptoms had abated.

Additional points raised during the discussion, included involving the private health sector in adherence monitoring, improved access to quality drugs, robust supply chains and the need for paediatric PQ formulations. Packaging aids such as blister packs or prepackaging compared to bulk package as well as pictorial inserts as suggested previously [17] were also deemed to be potential strategies (Table 3).

Topic 2: Tools and strategies used in other disease programs that can improve PQ adherence

Experiences from other disease programmes highlight the importance of adopting multiple approaches to improving adherence to treatment. A combination of efforts is needed and this should involve a multidisciplinary team of healthcare professionals (social workers, doctors, nurses, and counselors), patients (including close family members and carers) and the community (religious centres, community health organizations/agents and activists) [18]. Patient education and counseling were considered to be critical for all approaches, since both have been shown to improve patient-healthcare provider relationship, and provision of individualized and patient-centered care [19].

Education and counseling can be achieved at an individual level or at a family/group level. These approaches should include education about clinical consequences of vivax malaria, its propensity to recur and its treatment. Simple and pictorial stories and pamphlets can be used to increase patients' competencies and knowledge. Health

Table 3 Solutions to improve adherence to PQ

Main problem	Suitable interventions
Low patients adherence to PQ	Increase awareness among the general patient population about the benefits or radical cure through education and health promotion programs (health talks) and individual patients counseling Increased patient monitoring integrated into other disease programs, through home visits, incentives, pill boxes or automated reminders via text messages Packaging aids including pictorial inserts Better PQ formulations for children
Low provider adherence to PQ	Better staff training to increase awareness among staff about the benefits or radical cure and how to discuss these with patients Involvement of private sector in adherence monitoring. Improved access to quality drugs

talks to the general public attending the hospital or health centre to disseminate information about malaria and suitable preventive treatments were considered feasible. The provision of easy and low cost adherence aids can help patients remember their medications and the order and timing at which they should be taken. For instance, a pill box, in which doses are divided up by days or a pill taking table, can be filled in by the patient or someone supporting their treatment; these remind patients to take their medication, which tablets have already been taken and which tablets are still remaining. Alternative options include setting alarm clocks or mobile phone alarms to remind patients when to take the medication or matching pill taking to the patient's daily activities (e.g. before, or after a meal, or prior to a daily activity) [20]. Treatment support outside the health centre can be provided by either family members or community health agents. In Nepal a patient-responsive approach including both of these strategies has been shown to improve the adherence to tuberculosis treatment [21].

An integrated package of interventions was generally perceived to be more useful than single intervention. Furthermore the most suitable interventions are likely to be context specific. Thorough evaluation of the efficacy and effectiveness of new approaches including cost-benefit analyses is needed for National Malaria Control Programmes (NMCPs) to make informed decisions on optimal strategies.

Topic 3: Quantifying PQ effectiveness to optimize suitable interventions

Most anti-malarial clinical trials measure treatment efficacy, which refers to the ability of a regimen to achieve cure in an ideal scenario. Effectiveness is the extent to which a drug regimen achieves its intended effect in the real world setting. To determine effectiveness one needs to document the clinical outcome, such as recurrent episodes of malaria or associated anaemia, but in such a way as to minimize the influence on patient and prescriber behavior. Two questions were posed to participants: how

can adherence be measured reliably and how reactivity can be minimized without compromising the trial's integrity?

Typical measures of adherence include self-reporting, pill count and biological assays. Self-reporting is used widely since it is relatively easy and cheap to implement, however it is also subjective, highly dependent on how questions are asked, prone to recall and social desirability bias [22]. Using text messaging as a self-reporting tool was discussed as a potential way to reduce social desirability bias. Computer administration has been shown to increase reporting levels of sensitive questions compared to interviewer-based administration of questionnaires [22–24]. However interactive text-messaging relies on significant infrastructure and few studies have estimated its reliability [22].

Pill counts are also simple to implement using either manual counting or an electronic pill cap [25, 26]. Manual pill counts are usually undertaken during follow up visits at the health facility, with patients asked to bring the empty pill box or empty blister packs. However, this method is also prone to potential bias, since patients are aware that their compliance is being assessed. Home visits or unannounced calls to patients were discussed as a more appropriate to estimate true adherence, although this raises ethical considerations requiring prior consent when enrolled into the study [27, 28]. Electronic pill caps, were considered the reference standard of indirect adherence measures. These record the opening of the pill box, the underlying assumption being that bottle opening represents medication intake, however this level of complexity comes at a greater financial cost [29].

Biological assays offer another measure of adherence. Plasma drug concentrations can be quantified to demonstrate that drug doses were ingested, however these are confounded by the actual dose prescribed, its timing with respect to sampling, gastrointestinal absorption, metabolism and elimination. Furthermore such approaches require invasive sampling from either capillary or venous blood samples, and involve significant infrastructure

to ensure adequate sample storage and analysis. PQ is metabolized rapidly with a half-life of less than 6 h, so may be undetected within 24 h of administration [30]. Its metabolite, carboxy-PQ, is more slowly eliminated and accumulates over the course of a 14 day course and may therefore be a more useful measure of adherence [30]. Correlation of carboxy-PQ plasma concentrations and adherence requires knowledge of the normal pharmacokinetic profile of the drug when administered under supervision in a variety of populations; however this has yet to be defined. Sparse sampling similar to population pharmacokinetic studies with a probability score as outcome measure was discussed as a potential solution, but such approaches need to be validated in carefully controlled settings.

Quantifying methaemoglobin (Met-Hb) concentrations is another potential proxy measure of adherence. Met-Hb concentrations are elevated following PQ administration since the drug induces oxidative stress on red blood cells resulting in oxidation of the ferrous iron in the haem group [31]. Met-Hb can be measured non-invasively using a finger probe to measure arterial oxygen-Hb saturation. Similar to the interpretation of blood drug concentrations, the normal variation of Met-Hb following supervised PQ therapy needs to be defined. Furthermore Met-Hb concentration may be elevated due to other reasons besides PQ administration and thus validation of this approach is needed. A study in Bangladesh showed no clear correlation between Met-Hb levels and pill counts [32] and recent data from Brazil also indicated no correlation between the plasma PQ concentrations or total dose and Met-Hb levels [33], although further clinical studies are underway to explore this further.

Anti-malarial clinical efficacy trials require patient observation to capture the relevant study outcomes. However the act of observing people alters their behaviour, a phenomenon often described as reactivity or observation bias in psychological research and behavioural science [34–36]. Patients enrolled into a study often do not behave as they would in real life, just because they are aware that they are in a study, are being observed and receiving a therapeutic intervention. Comparative efficacy trials can mitigate this potential bias by “blinding” treatment so that either the patient and/or the clinician are unaware of the treatment arm they are receiving. Although this reduces behavioural bias between treatment arms being compared, it does not overcome changes in behaviour inherent in being under scrutiny. Hence adherence in intervention and control groups often do not reflect reality. Reactivity can be reduced by minimising observation or by using less

obtrusive measures, such as unannounced pill counts as discussed previously [28]. Early enrolment and consent of a cohort before malaria infection and treatment occurs, using a cluster design was suggested as a way to reduce reactivity as the effect can be expected to wane over time [36]. Studies that are integrated into the routine health care systems rather than stand-alone trials provide an alternative way of capturing clinical outcomes under normal clinical practice, although these are confounded by a lack of a control arm, residual confounding and attrition bias [10].

Topic 4: Increasing our understanding of effectiveness and adherence using mixed methods research

Reducing reactivity alone is insufficient to ensure robust measures of effectiveness or the effect of novel interventions targeting adherence. Measuring adherence and the factors that relate to it requires an in-depth understanding of the context and the underlying sociocultural logic that underlie it [37]. This requires a better understanding of the implicit heterogeneity in behaviour, cultural diversity and variability in social structural conditions underlying adherence.

Qualitative methods provide an important approach that can inform the optimal design of quantitative adherence studies. Contextual information can facilitate the selection processes to minimize bias, determine specific sub-groups at risk of being excluded, inform the operationalization of concepts to be measured, and aid the interpretation of the results. Suitable qualitative methods such as ethnography constitute effective tools to provide an in-depth understanding of the factors contributing to adherence. These data should be central to the design of appropriate intervention strategies to impact on behaviour and clinical outcomes. Quantitative measures of adherence need to consider the sociocultural specificities and thus are likely to vary considerably between different endemic settings. It is unlikely that a single approach can be proposed for suitable interventions or the design of an effectiveness trial that is widely applicable across a wide range of environments. However further exploration may reveal certain common elements that can be applied universally.

Various additional constraints for the delivery of effective radical cure were mentioned and considered to require a more in-depth and locally relevant understanding. These included human mobility and how this affects adherence and follow up, and patients' flexible health seeking itineraries and therapeutic choices, such as the private, traditional sectors and home treatment.

Conclusions

In the light of the 2030 elimination goal, the delivery of effective radical cure for malaria is a high priority for the vivax endemic areas of the Asia-Pacific Region, Horn of Africa and South and Meso-Americas. The design and evaluation of appropriate interventions to improve effectiveness of PQ treatment, as well as lessons learned from other disease programmes must be taken into account and the methodological challenges addressed.

Authors' contributions

KT, BL and RP conceived the idea and questions for the round table discussion; RP, ML, BH, KB, JH, WAK, IS, KB, CG, CvdB, RNB, KGP, EJ, LD, CG, MSA, EA, AP, JM, BT, JKB, FL, ME, PK, NA facilitated the discussions; all authors participated on the round table discussion; KT, KP, CG and RP wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Author details

¹ Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, Darwin, NT 0810, Australia. ² Ministry of Health and Medical Services, National Vector-Borne Disease Control Programme, Honiara, Solomon Islands. ³ Independent Consultant, Amsterdam, The Netherlands. ⁴ International Center for Diarrheal Diseases (ICDDR,B), Dhaka, Bangladesh. ⁵ Myanmar-Oxford Clinical Research Unit, Yangon, Myanmar. ⁶ Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. ⁷ Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia. ⁸ Institute of Tropical Medicine Antwerp, Antwerp, Belgium. ⁹ Medicines for Malaria Venture (MMV), Geneva, Switzerland. ¹⁰ Instituto Leônidas & Maria Deane (Fiocruz), Manaus, Amazonas, Brazil. ¹¹ Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil. ¹² National Forum on Indonesia RBM/National Forum on Gebrak Malaria, Jakarta, Indonesia. ¹³ Universitas Sumatera Utara, Medan, Indonesia. ¹⁴ Yayasan Pengembangan Kesehatan dan Masyarakat, Papua (YPKMP), Papua, Indonesia. ¹⁵ University of Indonesia, Jakarta, Indonesia. ¹⁶ Mahidol Oxford Clinical Research Unit (MORU), Bangkok, Thailand. ¹⁷ Malaria Atlas Project (MAP), Big Data Institute, University of Oxford, Oxford, UK. ¹⁸ National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia. ¹⁹ School of Public Health, National Institute of Public Health, Phnom Penh, Cambodia. ²⁰ Microbiology Department, Tribhuvan University, Kathmandu, Nepal. ²¹ Entomology Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, USA. ²² President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, USA. ²³ Global Health Group, University of California San Francisco, San Francisco, USA. ²⁴ Disease Control Division, Ministry of Health, Putrajaya, Malaysia. ²⁵ UNICEF Indonesia, Jakarta, Indonesia. ²⁶ Liverpool School of Tropical Medicine, Liverpool, UK. ²⁷ Directorate General of Health Services, Ministry of Health & Family Welfare Government of the People's Republic of Bangladesh, Dhaka, Bangladesh. ²⁸ Save The Children, Kathmandu, Nepal. ²⁹ ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain. ³⁰ Intellectual Ventures Global Good Fund, Bellevue, USA. ³¹ The London School of Hygiene & Tropical Medicine (LSHTM), London, UK. ³² Australian Defence Force Malaria and Infectious Disease Institute, Enoggera, Australia. ³³ Center of Malariology, Parasitology and Entomology, Communicable Diseases Control, Vientiane, Lao PDR. ³⁴ Bill & Melinda Gates Foundation, Seattle, USA. ³⁵ Indian Council of Medical Research, New Delhi, India. ³⁶ Department of Health, National Centre for Disease Control & Prevention, Manila, Philippines. ³⁷ Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, USA. ³⁸ PATH, Seattle, USA. ³⁹ National Institute of Parasitic Diseases, China CDC, Shanghai, China. ⁴⁰ WHO Office, Jakarta, Indonesia. ⁴¹ ACTMalaria, Manila, Philippines. ⁴² Ministry of Health, National Malaria Control Program, Jakarta, Indonesia. ⁴³ Tengchong Center for Disease Control and Prevention, Tengchong, China. ⁴⁴ Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. ⁴⁵ Epidemiology & Disease Control Division, Department of Health Services, Ministry of Health and Population, Kathmandu, Nepal. ⁴⁶ Papuan Health and Community Development Foundation, Timika, Indonesia. ⁴⁷ Ministry of Health, Kathmandu, Nepal. ⁴⁸ Division of Vectors and Parasitic Diseases, Korea Centers for Disease Control and Prevention, Seoul, South Korea. ⁴⁹ Ministry of Health, National Malaria Control Programme,

Port Mosby, Papua New Guinea. ⁵⁰ QIMR Berghofer Medical Research Institute, Brisbane, Australia. ⁵¹ School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia. ⁵² Ministry of Health, Malaria and Other Vector-Borne Diseases Control Program (MOVBDPC), Port Vila, Vanuatu. ⁵³ National Institute of Malariology, Parasitology and Entomology (NIMPE), Hanoi, Vietnam. ⁵⁴ Eijkman Institute for Molecular Biology, Jakarta, Indonesia. ⁵⁵ Jiangsu Institute of Parasitic Diseases, Wuxi, China. ⁵⁶ WHO Collaborative Centre for Research and Training of Malaria Elimination, Wuxi, China. ⁵⁷ Tuberculosis-HIV Research Center Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia. ⁵⁸ Radboud University Nijmegen, Nijmegen, The Netherlands. ⁵⁹ Department of Medicine at the Doherty Institute, University of Melbourne, Melbourne, Australia. ⁶⁰ Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Bangkok, Thailand. ⁶¹ National Vector Borne Disease Control Programme Directorate General of Health Services Ministry of Health & Family Welfare, New Delhi, India. ⁶² WorldWide Antimalarial Resistance Network (WWARN), Oxford, UK. ⁶³ University of Washington, Seattle, WA, USA. ⁶⁴ Family Health Directorate, Ministry of Health, Jakarta, Indonesia. ⁶⁵ Medicine Department, Medical College Kolkata, Kolkata, India. ⁶⁶ Kenya Medical Research Institute (KEMRI) Centre for Global Health Research, Kisumu, Kenya. ⁶⁷ Family Health Services, Ministry of Health, Port Mosby, Papua New Guinea. ⁶⁸ Freeport Indonesia, Kuala Kencana, Indonesia. ⁶⁹ Ethiopian Public Health Institute (EPHI), Addis Ababa, Ethiopia. ⁷⁰ Independent Consultant, Bangkok, Thailand. ⁷¹ Yonsei University College of Medicine, Seoul, South Korea. ⁷² Program and Information Department, Directorate General of Disease Prevention and Control, Jakarta, Indonesia. ⁷³ University of Gadjah Mada, Yogyakarta, Indonesia.

Acknowledgements

We would like to thank all participants of the annual meeting and the Indonesian NMCP for hosting this event.

Competing interests

The authors declare that they have no competing interest.

Availability of data and materials

Not applicable.

Consent for publication

All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Funding

The meeting was funded through a grant from the Bill and Melinda Gates Foundation (OPP1164105) to the Asia Pacific Malaria Elimination Network (APMEN) Vivax Working Group (VxWG). The meeting was held in conjunction with the Malaria in Pregnancy Consortium (MIP) and back to back with the Medicines for Malaria Venture (MMV) stakeholder meeting who provided additional support for the meeting. Further support for the meeting was provided through a grant from the Department of Foreign Affairs and Trade (DFAT) supported by the Australian Government [Grant Agreement Number 72904]. KT, BL and JM are funded by the Asia Pacific Malaria Elimination Network (APMEN) and OPRA clinical trial funding, supported by the Bill & Melinda Gates Foundation (OPP1164105 and OPP1054404). NMA is supported by and NHMRC Research Fellowship (1135820).

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 May 2018 Accepted: 8 June 2018

Published online: 20 June 2018

References

- Chairman's Statement of the 9th East Asia Summit. <http://dfat.gov.au/international-relations/regional-architecture/eas/Pages/chairmans-statement-of-the-9th-east-asia-summit.aspx>. Accessed 12 June 2018.

2. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. *Malar J*. 2014;13:418.
3. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
4. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of *Plasmodium vivax*: a critical review of the literature. *Malar J*. 2012;11:280.
5. Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of *Plasmodium vivax* infection in Ethiopia: a randomized controlled trial. *PLoS Med*. 2017;14:e1002299.
6. Pereira EA, Ishikawa EA, Fontes CJ. Adherence to *Plasmodium vivax* malaria treatment in the Brazilian Amazon Region. *Malar J*. 2011;10:355.
7. Maneeboonyang W, Lawpoolsri S, Puangsa-Art S, Yimsamran S, Thanayanich N, Wuthisen P, et al. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. *Southeast Asian J Trop Med Public Health*. 2011;42:9–18.
8. Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukritayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of *Plasmodium vivax* malaria on the Thai-Myanmar border. *Malar J*. 2010;9:308.
9. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. *J Health Popul Nutr*. 2009;27:4–13.
10. Douglas NM, Poesoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugianto P, et al. Unsupervised primaquine for the treatment of *Plasmodium vivax* malaria relapses in southern Papua: a hospital-based cohort study. *PLoS Med*. 2017;14:e1002379.
11. IMPROV study group. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. *BMC Infect Dis*. 2015;15:558.
12. Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7-day primaquine treatment for the radical cure of *P. vivax* in the Peruvian Amazon. *Am J Trop Med Hyg*. 2010;82:1017–23.
13. Vivax Working Group. Targeting vivax malaria in the Asia Pacific: the Asia Pacific Malaria Elimination Network Vivax Working Group. *Malar J*. 2015;14:484.
14. Gryseels C, Uk S, Erhart A, Gerrets R, Sluydts V, Durnez L, et al. Injections, cocktails and diviners: therapeutic flexibility in the context of malaria elimination and drug resistance in Northeast Cambodia. *PLoS ONE*. 2013;8:e80343.
15. Kamat VR. Cultural interpretations of the efficacy and side effects of antimalarials in Tanzania. *Anthropol Med*. 2009;16:293–305.
16. Ley B, Thriemer K, Jaswal J, Poirot E, Alam MS, Phru CS, et al. Barriers to routine G6PD testing prior to treatment with primaquine. *Malar J*. 2017;16:329.
17. Fuangchan A, Dhippayom T, Kongkaew C. Intervention to promote patients' adherence to antimalarial medication: a systematic review. *Am J Trop Med Hyg*. 2014;90:11–9.
18. Institute of Medicine (US) Committee on Health and Behavior: Research, Practice, and Policy. 5. Individuals and families: models and interventions. In: Health and behavior: the interplay of biological, behavioral, and societal influences. Washington (DC): National Academies Press (US); 2001.
19. WHO. Therapeutic patient education: continuing education programmes for healthcare providers in the field of prevention of chronic diseases, report of a WHO working group. Geneva: WHO; 1998.
20. Atreja A, Bellam N, Levy SR. Strategies to enhance patient adherence: making it simple. *MedGenMed*. 2005;7:4.
21. Newell JN, Baral SC, Pande SB, Bam DS, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. *Lancet*. 2006;367:903–9.
22. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. *Transl Behav Med*. 2015;5:470–82.
23. Islam MM, Topp L, Conigrave KM, van Beek I, Maher L, White A, et al. The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician-administered versus audio computer-assisted self-interviewing (ACASI). *AIDS Care*. 2012;24:1496–503.
24. Newman JC, Des Jarlais DC, Turner CF, Gribble J, Cooley P, Paone D. The differential effects of face-to-face and computer interview modes. *Am J Public Health*. 2002;92:294–7.
25. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. *JAMA*. 1989;261:3273–7.
26. Hayes TL, Hunt JM, Adami A, Kaye JA. An electronic pillbox for continuous monitoring of medication adherence. *Conf Proc IEEE Eng Med Biol Soc*. 2006;1:6400–3.
27. Fredericksen R, Feldman BJ, Brown T, Schmidt S, Crane PK, Harrington RD, et al. Unannounced telephone-based pill counts: a valid and feasible method for monitoring adherence. *AIDS Behav*. 2014;18:2265–73.
28. Goodwin KA, Goodwin CJ. Observational research. In: Visentin V, editor. Research in psychology methods and design; 2017. p. 297.
29. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther*. 1999;21:1074–90 (discussion 1073).
30. Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. *Br J Clin Pharmacol*. 1984;17:441–6.
31. Coleman MD, Coleman NA. Drug-induced methaemoglobinemia. Treatment issues. *Drug Saf*. 1996;14:394–405.
32. Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. *PLoS ONE*. 2016;11:e0154015.
33. Vieira JL, Ferreira MES, Ferreira MVD, Gomes MM. Primaquine in plasma and methemoglobinemia in patients with malaria due to *Plasmodium vivax* in the Brazilian Amazon Basin. *Am J Trop Med Hyg*. 2017;96:1171–5.
34. Onghena P. Reactivity. In: Everitt BS, Howell DC, editors. Encyclopedia of statistics in behavioral science. Hoboken: John Wiley & Sons, Ltd; 2005.
35. French P, Sutton S. Methods: does measuring people change them? *Psychologist*. 2011;24:272–4.
36. Given L. The SAGE encyclopedia of qualitative research methods. Thousand Oaks: Sage Publications; 2008.
37. Muela Ribera J, Hausmann-Muela S, Gryseels C, Peeters Grietens K. Re-imagining adherence to treatment from the "other side": local interpretations of adverse anti-malarial drug reactions in the Peruvian Amazon. *Malar J*. 2016;15:136.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

